We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+10.48%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.76B
AUM Growth
+$143M
Cap. Flow
-$59.1M
Cap. Flow %
-2.14%
Top 10 Hldgs %
30.84%
Holding
95
New
14
Increased
24
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$38.3M
2
HCA icon
HCA Healthcare
HCA
+$34.9M
3
BIIB icon
Biogen
BIIB
+$29.6M
4
PEN icon
Penumbra
PEN
+$28.4M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$24.6M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$80.8M
2
PFE icon
Pfizer
PFE
+$70.4M
3
MRK icon
Merck
MRK
+$54.6M
4
BDX icon
Becton Dickinson
BDX
+$32.2M
5
UHS icon
Universal Health Services
UHS
+$32M

Sector Composition

Rank Sector Weight
1 Healthcare 88.58%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$11.2B
$119M 4.32%
2,465,016
– –
LLY icon
2
Eli Lilly
LLY
$1.04T
$96.6M 3.49%
298,643
– –
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.3B
$94.6M 3.42%
1,115,949
+276,578
+33% +$24.6M
RCUS icon
4
Arcus Biosciences
RCUS
$3.77B
$88.5M 3.2%
3,383,233
+36,775
+1% +$973K
CNC icon
5
Centene
CNC
$32.5B
$86.6M 3.13%
1,112,480
– –
HUM icon
6
Humana
HUM
$47.7B
$80.6M 2.92%
166,066
– –
JAZZ icon
7
Jazz Pharmaceuticals
JAZZ
$15.7B
$76.2M 2.76%
571,936
– –
AXSM icon
8
Axsome Therapeutics
AXSM
$12.3B
$74.1M 2.68%
1,659,733
+299,137
+22% +$14.9M
PEN icon
9
Penumbra
PEN
$12.4B
$68.3M 2.47%
360,030
+177,244
+97% +$28.4M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$67.6M 2.44%
1,091,840
– –
CRBU icon
11
Caribou Biosciences
CRBU
$165M
$63.3M 2.29%
6,000,000
– –
IRTC icon
12
iRhythm Holdings
IRTC
$3.49B
$61.9M 2.24%
493,721
– –
ERAS icon
13
Erasca
ERAS
$6.77B
$56.7M 2.05%
7,264,981
+1,383,599
+24% +$11.1M
UNH icon
14
UnitedHealth
UNH
$392B
$56.3M 2.04%
111,554
– –
PRTA icon
15
Prothena Corp
PRTA
$442M
$50.9M 1.84%
840,238
+495,124
+143% +$15.7M
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
$50M 1.81%
365,215
+82,820
+29% +$13.5M
MOH icon
17
Molina Healthcare
MOH
$11.6B
$47.4M 1.72%
143,779
– –
XLK icon
18
PUT
State Street Technology Select Sector SPDR ETF
XLK
$117B
$45.6M 1.65%
+767,000
New +$52.3M
DHR icon
19
Danaher
DHR
$127B
$45.4M 1.64%
198,178
– –
QURE icon
20
uniQure
QURE
$2.78B
$44.9M 1.62%
2,393,311
+156,941
+7% +$3.3M
BIIB icon
21
CALL
Biogen
BIIB
$29.2B
$44.5M 1.61%
166,800
– –
CAH icon
22
Cardinal Health
CAH
$51.7B
$42.7M 1.54%
639,783
– –
ABBV icon
23
AbbVie
ABBV
$448B
$42.6M 1.54%
317,163
+70,928
+29% +$10.2M
IQV icon
24
IQVIA
IQV
$33.1B
$41.5M 1.5%
229,081
+7,385
+3% +$1.62M
AVTR icon
25
Avantor
AVTR
$7.48B
$40.8M 1.47%
2,079,657
– –
1
2 3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q3 2022 Portfolio in Review

As of Q3 2022, PFM Health Sciences held 95 positions worth $2.76B, up 5.4% from $2.62B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

PFM Health Sciences's Q3 2022 filing shows 14 new, 24 increased, 13 reduced and 10 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 4,515,216 shares worth $34.9M. The largest sale was Johnson & Johnson, an estimated $80.8M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 94% a quarter earlier, followed by Financials.

  • PFM Health Sciences's largest Q3 2022 buy was POINT Biopharma Global Inc. Common Stock: 4,515,216 shares worth $34.9M.
  • PFM Health Sciences added most to Penumbra in Q3 2022, an estimated $28.4M increase.
  • PFM Health Sciences's biggest Q3 2022 reduction was Johnson & Johnson, cutting an estimated $80.8M.
  • PFM Health Sciences fully exited Pfizer in Q3 2022, selling an estimated $70.4M.
  • PFM Health Sciences's ten largest holdings make up 31% of its $2.76B portfolio in Q3 2022.
  • PFM Health Sciences opened 14 new positions and closed 10 in Q3 2022.
  • PFM Health Sciences's portfolio value rose 5.4% quarter-over-quarter to $2.76B.

Based on PFM Health Sciences's 13F filing for Q3 2022, filed 14 Nov 2022.